Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTOR | P42345 | 3/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | TRPV1 | Q8NER1 | 5/20 | 0.37 |
| ▸ | GRIN2B | Q13224 | 5/20 | 0.37 |
| ▸ | NAMPT | P43490 | 1/20 | 0.36 |
| ▸ | CCR3 | P51677 | 1/20 | 0.35 |
| ▸ | CNR1 | P21554 | 1/20 | 0.35 |
| ▸ | HTR1A | P08908 | 1/20 | 0.34 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.34 |
| ▸ | PARP1 | P09874 | 1/20 | 0.34 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL185770 | 0.87 | TRPV1 (0.39) | MAPK1TRPV1NAMPT | |
| SCHEMBL186522 | 0.87 | PDE10A (0.38) | MTORMAPK1TRPV1NAMPTCNR1 | |
| SCHEMBL186739 | 0.87 | TRPV1 (0.39) | MAPK1TRPV1GRIN2B | |
| SCHEMBL186668 | 0.87 | CCNC (0.44) | MAPK1TRPV1NAMPT | |
| SCHEMBL187553 | 0.86 | TRPV1 (0.38) | MAPK1TRPV1NAMPT | |
| SCHEMBL186422 | 0.85 | NAMPT (0.38) | MAPK1TRPV1NAMPTCNR1P2RX7 | |
| SCHEMBL187250 | 0.85 | TRPV1 (0.41) | MAPK1TRPV1GRIN2BNAMPTCNR1 | |
| SCHEMBL186012 | 0.84 | MAPT (0.44) | MAPK1TRPV1NAMPTCNR1 | |
| SCHEMBL185941 | 0.83 | TRPV1 (0.40) | MAPK1TRPV1GRIN2BNAMPTPARP1 | |
| SCHEMBL186996 | 0.83 | TRPV1 (0.39) | MAPK1TRPV1GRIN2BNAMPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8193190-B2 | Derivatives of (bridged piperazinyl)-1-alkanone and use thereof as p75 inhibitors | SANOFI-AVENTIS (FR) | 2012-06-05 | — | — | US | claimed |
| EP-2297148-B1 | NOVEL DERIVATIVES OF (BRIDGED PIPERAZINYL)-1-ALCANONE AND USE THEREOF AS P75 INHIBITORS | SANOFI SA (FR) | 2012-01-04 | — | — | EP | claimed |
| US-20110144116-A1 | DERIVATIVES OF (BRIDGED PIPERAZINYL)-1-ALKANONE AND USE THEREOF AS p75 INHIBITORS | SANOFI-AVENTIS (FR) | 2011-06-16 | — | — | US | claimed |
| US-8519143-B2 | Derivatives of (bridged piperazinyl)-1-alkanone and use thereof as p75 inhibitors | SANOFI (FR) | 2013-08-27 | — | — | US | disclosed |
| US-20120232280-A1 | DERIVATIVES OF (BRIDGED PIPERAZINYL)-1-ALKANONE AND USE THEREOF AS p75 INHIBITORS | SANOFI-AVENTIS (FR) | 2012-09-13 | — | — | US | disclosed |
| US-8193190-B2 | Derivatives of (bridged piperazinyl)-1-alkanone and use thereof as p75 inhibitors | SANOFI-AVENTIS (FR) | 2012-06-05 | — | — | US | disclosed |
| US-20110144116-A1 | DERIVATIVES OF (BRIDGED PIPERAZINYL)-1-ALKANONE AND USE THEREOF AS p75 INHIBITORS | SANOFI-AVENTIS (FR) | 2011-06-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110144116-A1 | DERIVATIVES OF (BRIDGED PIPERAZINYL)-1-ALKANONE AND USE THEREOF AS p75 INHIBITORS | NGF, NTRK2, NTRK3 | MTOR 2620/4885MAPK1 981/4885TRPV1 1056/4885 |
| US-20120232280-A1 | DERIVATIVES OF (BRIDGED PIPERAZINYL)-1-ALKANONE AND USE THEREOF AS p75 INHIBITORS | NGF, NTRK2, NTRK3 | MTOR 2620/4885MAPK1 981/4885TRPV1 1056/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.